ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Real-Time In Vivo Visualization of Tumor-Associated Macrophage Reprogramming Using a Nitric Oxide-Activatable NIR-II Nanoinducer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tumor-associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME). They typically adopt an M2-like phenotype that promotes tumor progression by providing survival signals, suppressing anti-tumor immunity, and facilitating pre-metastatic niche formation. Reprogramming TAMs toward an anti-tumor phenotype has emerged as a promising therapeutic strategy, with the repolarization of M2-like TAMs into an M1-like phenotype being central to this approach. Here, a nitric oxide (NO)-activatable near-infrared-II (NIR-II) fluorescence/photoacoustic nanoinducer (I/E@M2pep) that selectively targets M2-like TAMs and reprograms them toward an M1-like phenotype, thereby enhancing anti-tumor efficacy is reported. In this construct, the M2pep peptide enables M2-like TAM targeting, IPI549 reprograms them toward an M1-like phenotype while inducing NO production, and the NO-activatable NIR-II probe (ETNO) allows for in vivo visualization of macrophage repolarization via NIR-II fluorescence/photoacoustic imaging. In a mouse breast cancer model, intravenous administration of I/E@M2pep produced a ratiometric NIR-II photoacoustic signal change that correlated with M2-to-M1 repolarization. Furthermore, combining this nanoinducer with a CD47 monoclonal antibody markedly enhanced anti-tumor immunity through M1 macrophage-mediated tumor killing and TME remodeling. This work presents an effective in vivo strategy that simultaneously facilitates and visualizes TAM repolarization, holding promise for broader applications in studying tumor initiation, metastasis, and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.